Send us a text

Dr. Rose Loughlin, Ph.D. is Executive Vice President, Research at Moderna ( https://www.modernatx.com/en-US ), a biotech company harnessing the power of mRNA technology to develop a new class of medicine for a range of unmet medical needs.

Dr. Loughlin leads the company’s platform science and therapeutics research organization, focusing on pioneering scientific advancements and further strengthening the Moderna’s innovative pipeline.

Dr. Loughlin previously served as Senior Vice President of Research and Early Development at Moderna, where she played a crucial role in advancing the Company's portfolio and platform strategy since joining in 2016. 

Before joining Moderna, Dr. Loughlin held roles at Biogen in business development and at L.E.K. Consulting, where she contributed to defining corporate and portfolio growth strategies for biopharmaceutical companies.

Dr. Loughlin holds a Ph.D. in Biophysics from the University of California, Berkeley, and a Bachelor of Arts in physics from Harvard University, and did post-doc work in Germany at European Molecular Biology Laboratory.

#RoseLoughlin #Moderna #mRNA #MessengerRNA #CancerVaccines #NeoantigenTherapy #Melanoma #RareDisease #IntercellularTherapeutics #PropionicAcidemia #MethylmalonicAcidemia #CMV #Cytomegalovirus  #EpsteinBarrVirus #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show